STAT+: FDA finalists under review

STAT PlusNewsletterD.C. Diagnosis FDA finalists under review You’re reading STAT’s D.C. Diagnosis newsletter Manage alerts for this article Email this article Share this article By John WilkersonJuly 9, 2026 Washington Correspondent John Wilkerson[email protected]John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. I’m only just learning about the Norse soccer god Erling Haaland, who lives on copious amounts of organ meat and raw milk. Send news tips and “ancestral diets” to [email protected] or John_Wilkerson.07 on Signal.Advertisement ACA premium spikes, and a thong-clad chicken suit There are many reasons to care about the skyrocketing cost of ACA marketplace plans costs. One of them is the impact on small businesses. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In CMS, drug development, FDA, HHS, Medicare, Pharmaceuticals, Policy, public health, research, STAT+ Submit a correction requestReprints John Wilkerson Washington Correspondent John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. Newsletter The latest updates in federal health agencies, research institutes, and U.S. policy Recommended The Readout July 9, 2026 STAT Plus: Prime wins Beam arbitration, clearing path to clinic Exclusive July 8, 2026 STAT Plus: In private meeting, Trump officials push to onshore generic drugmaking Advertisement The Readout July 8, 2026 STAT Plus: Europe will accelerate its review of RevMed’s drug D.C. Diagnosis July 7, 2026 STAT Plus: The crumbling employer-based health insurance system The Readout July 7, 2026 STAT Plus: Compass says depression drug has long-lasting benefits Subscriber Picks